Log in with your email address username.


[Correspondence] Changes in the primary outcome in Ebola vaccine trial

We read with interest Ana Maria Henao-Restrepo and colleagues’ Article (Aug 3, p 857)1 on the ring vaccination trial of an rVSV-vectored vaccine for Ebola virus disease. This trial represents a fantastic effort in a very short space of time and in challenging circumstances. WHO sponsored the trial, offering the opportunity to show best practices in the design, conduct, and reporting of trials.2